Fig. 1From: Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label studyChange in plasma lyso-Gb3 in males and females (efficacy population). Anti-pegunigalsidase alfa ADA assessment was conducted at baseline, Weeks 4, 8, 12, 16, 20, 26, 38, and 52; positive status is shown with an x. ADA, antidrug antibodyBack to article page